Search results for " Drug"

showing 10 items of 3138 documents

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C

2010

Purpose Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs. Methods Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting. Results Eighty-four percent of patients experienced at least one adverse event (853 events in total, 3.3 per patient on average). Incidence rate was higher during the first 90 days and decreased thereafter (<5%). Discontinuation rates at 30 and 90 days and at end of treatment were 2, 4 and 8%, re…

AdultMalemedicine.medical_specialtyGenotypeEpidemiologyadverse eventHepacivirusAntiviral AgentsSettore MED/01 - Statistica MedicaMedication Adherencechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinHumansMedicinePharmacology (medical)Dual therapyAdverse effectDose ModificationSettore MED/12 - GastroenterologiaDose-Response Relationship Drugbusiness.industryIncidenceRibavirinAge FactorsAntiviral therapyInterferon-alphainterferonpredictionHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryDiscontinuationchemistryDrug Therapy CombinationFemalehepatitis CbusinessPharmacoepidemiology and Drug Safety
researchProduct

Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months

2000

Abstract Background/Aims: Retreatment of relapses of chronic hepatitis C with a standard regimen of interferon plus ribavirin for 6 months obtains a sustained response in a minority of patients with high viraemia and genotype 1b . We aimed to assess whether increasing the interferon dose and prolonging the time of combined treatment may enhance the effectiveness, and also to evaluate the tolerability, and to identify the determinants of sustained response. Methods: Fifty subjects with chronic hepatitis C who had relapsed after one or more courses of α-interferon monotherapy were randomised to receive α 2 b interferon (6 MU tiw) plus ribavirin (1000–1200 mg daily) for 6 or 12 months. ALT nor…

AdultMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentAlpha interferonHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRecurrenceInterferonInternal medicineRibavirinmedicineHumansInterferon alfaChemotherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C ChronicMiddle AgedRecombinant ProteinsAnti-Bacterial AgentsSurgeryRegimenTreatment OutcomechemistryTolerabilityRNA ViralDrug Therapy CombinationFemaleComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.

2019

Itch is the most bothersome symptom in psoriasis, often leading to impaired quality of life. Treatment of psoriasis-induced itch is frequently unsatisfactory as the various therapies employed have a delayed onset of effect. Histamine-1 receptor (H1) antihistamines are not recommended in treatment guidelines as histamine is not considered a key mediator in psoriasis. However, patients using H1 antihistamines frequently report benefits in questionnaire-based studies. To address these contradictions, we examined the short-term effects of levocetirizine, a nonsedating H1 antihistamine, on psoriasis-related itch and itch-related quality of life. In this pilot study, patients with psoriasis-relat…

AdultMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingTime FactorsPilot ProjectsDermatologyLevocetirizine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesPsoriasisparasitic diseasesotorhinolaryngologic diseasesMedicineEffective treatmentHumansPsoriasisskin and connective tissue diseasesH1 antihistamineDose-Response Relationship Drugbusiness.industryPruritusDelayed onsetGeneral MedicineMiddle Agedmedicine.diseaseDermatologyeye diseasesCetirizineTreatment Outcome030220 oncology & carcinogenesisConcomitantQuality of LifeFemaleOpen labelbusinessmedicine.drugDermatologic therapyREFERENCES
researchProduct

Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

AdultMalemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismGrowth hormoneGrowth hormone deficiency03 medical and health sciencesInsulin-like growth factor0302 clinical medicineEndocrinologySex FactorsInternal medicineGermanymedicineHumansDosingDwarfism PituitaryAgedDose-Response Relationship Drugbusiness.industryHuman Growth HormoneAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseClinical PracticeEndocrinologyTreatment OutcomeTransgender hormone therapy030220 oncology & carcinogenesisGh treatmentFemalebusinessReal world dataGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients

1999

Abstract Background: The adenylyl cyclase (AC) signal transduction pathway is a target of acute and chronic ethanol actions. This study examined whether AC activity in lymphocyte membranes of male alcoholic patients correlated with blood concentrations of ethanol. Methods: Patients ( n = 13; mean age: 40 ± 8 years) were studied on the day of admission (day 0) and 2 days later under detoxification. Moreover, 13 age-matched male healthy controls (mean age 40 ± 9 years) were included. Lymphocyte membranes were prepared by differential centrifugation whereby blood ethanol was washed out. As a measure of AC activity the formation of cyclic adenosine monophosphate (cAMP) from adenosine triphospha…

AdultMalemedicine.medical_specialtyLymphocyteStimulationGuanosine triphosphateAdenylyl cyclasechemistry.chemical_compoundAdenosine TriphosphateInternal medicineCyclic AMPmedicineHumansCyclic adenosine monophosphateLongitudinal StudiesLymphocytesBiological PsychiatryEthanolForskolinDose-Response Relationship DrugEthanolColforsinMiddle AgedAlcoholismmedicine.anatomical_structureEndocrinologychemistryCase-Control StudiesGuanosine TriphosphatePhosphorus RadioisotopesAdenosine triphosphateAdenylyl CyclasesSignal TransductionBiological Psychiatry
researchProduct

A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.

2002

Ftorafur is an orally available prodrug of 5-fluorouracil (5-FU). Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone. Paclitaxel has a broad spectrum of activity against solid tumors and synergic effects with UFT have been demonstrated in vitro. A phase I study was performed to determine the maximum tolerated dose of the combination of UFT and paclitaxel in patients with advanced solid tumors.UFT and folinic acid were applied at 300 mg/m2/day and 90 mg/day, respectively, on days 1-28, repeated on day 36. Paclitaxel was applied on days 1, 8, 15 and 22 of each cycle. The starting dose of paclitaxel was 50 mg/m…

AdultMalemedicine.medical_specialtyMaximum Tolerated DosePaclitaxelmedicine.medical_treatmentLeucovorinAdministration OralPharmacologyTegafurGastroenterologyDrug Administration Schedulechemistry.chemical_compoundFolinic acidLeukocytopeniaOral administrationInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedTegafurChemotherapyDose-Response Relationship Drugbusiness.industryHematologyMiddle AgedSurvival AnalysisTreatment OutcomeOncologyPaclitaxelchemistryFluorouracilToxicityFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study

2009

There is ample evidence to support the efficacy of sublingual immunotherapy (SLIT) on allergic rhinitis, while there is less solid data regarding asthma. We evaluated the effects of a high dose birch SLIT on birch-induced rhinitis and asthma in a controlled study.This double-blind, placebo-controlled, randomised, single centre trial on SLIT with birch pollen allergen extract (Stallergenes, Antony, France) included 24 patients presenting severe rhinitis and slight to moderate asthma, 14 actively and 10 placebo treated. SLIT was performed by a pre-coseasonal protocol, and was repeated for 2 years. The study plan included a selection visit, a visit at the start of the first and the second trea…

AdultMalemedicine.medical_specialtyModerate asthmaDouble-Blind Method; Humans; Immunotherapy; Seasons; Adult; Asthma; Placebos; Pilot Projects; Middle Aged; Male; Female; Drug Administration RoutesPilot ProjectsPlacebolaw.inventionPlacebosSeasonal asthmaRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansSublingual immunotherapyPilot ProjectPlaceboAsthmabusiness.industryDrug Administration RoutesGeneral MedicineMiddle Agedmedicine.diseaseSlitAsthmaSurgerySingle centreFemaleSeasonsImmunotherapySeasonSLIT asthma allergybusinessHuman
researchProduct

A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction

1993

A double-blind parallel-group comparison study of moclobemide versus doxepin in 237 patients with major depression confirmed that moclobemide was equal in efficacy and better tolerated than doxepin. It was less sedating and caused fewer anticholinergic adverse events as measured by the UKU side-effect rating scale. Unexpectedly, moclobemide therapy more often than doxepin resulted in increased sexual desire. An exploratory analysis of UKU-measured symptoms of impaired sexual function prior to commencement of the study revealed that moclobemide more often than doxepin led to an improvement of reduced libido and impaired erection, ejaculation and orgasm. This finding is compatible with the as…

AdultMalemedicine.medical_specialtyMonoamine Oxidase InhibitorsPersonality Inventorymedicine.drug_classLibidoMoclobemideSexual BehaviorDouble-Blind MethodMoclobemidemedicineAnticholinergicHumansPharmacology (medical)PsychiatryAdverse effectDepression (differential diagnoses)Depressive DisorderDose-Response Relationship DrugMiddle AgedDoxepinPsychiatry and Mental healthSexual dysfunctionAnesthesiaBenzamidesComparison studyFemaleDoxepinmedicine.symptomPsychologymedicine.drugInternational Clinical Psychopharmacology
researchProduct

Relaxation by β3-adrenoceptor agonists of the isolated human internal anal sphincter

2009

In this study, responses of beta(3)-adrenoceptor agonists were examined on human isolated internal anal sphincter (IAS) in order to explore their relaxant effects on hypertonicity of IAS.The relaxant efficacy (E(max)) and potency (-logIC(50)) of BRL37344 and SR58611A, beta(3)-adrenoceptor agonists, were examined in contracted IAS muscle strips. The presence of beta(3)-adrenoceptors, and changes in intracellular calcium and cyclic nucleotide levels in IAS muscle were tested by Western blotting, epifluorescence microscopy and enzyme immunoassay, respectively.BRL37344 and SR58611A relaxed contracted IAS muscle (E(max)=27+/-3% and 35+/-3%; -logIC(50)=6.26+/-0.24 and 4.87+/-0.13; respectively). …

AdultMalemedicine.medical_specialtyMuscle RelaxationAnal CanalAdrenergic beta-3 Receptor AgonistsIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyCalcium in biologyInternal anal sphincterInternal medicinemedicineHumansPotencyGeneral Pharmacology Toxicology and PharmaceuticsAgedAged 80 and overDose-Response Relationship DrugRelaxation (psychology)Sphincter tonebusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle AgedEndocrinologyEthanolaminesReceptors Adrenergic beta-3Femaleβ3 adrenoceptorbusinessLife Sciences
researchProduct

Cisplatin preparation error; patient management and morbidity

2009

Introduction. Antineoplastic drug therapy errors represent a high iatrogenic potential due to antineoplastic drugs narrow therapeutic ranges and the complexity of chemotherapy regimens that may increase the risk of morbidity and mortality for oncology patients.Setting. We report a 57-year-old man with head and neck cancer who mistakenly received 180 mg/ m2of cisplatin overdose despite the safety measures and validations carried out during preparation. The patient developed moderate nausea and vomiting, acute renal failure, hearing difficulty (tinnitus), and severe myelodepression.Patient management. Prophylactic and symptomatic treatments were applied in order to prevent and correct toxicit…

AdultMalemedicine.medical_specialtyNauseaDrug CompoundingAntineoplastic drugmedicine.medical_treatmentAntineoplastic AgentsDrug overdoseMedication errorTinnitusmedicineHumansPharmacology (medical)Intensive care medicineBone Marrow DiseasesCisplatinChemotherapyMedical Errorsbusiness.industryNauseaAcute Kidney Injurymedicine.diseasePatient managementSurgeryOncologyHead and Neck NeoplasmsAntineoplastic DrugsCisplatinDrug Overdosemedicine.symptombusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct